S
Scott D. Rowley
Researcher at Hackensack University Medical Center
Publications - 85
Citations - 2505
Scott D. Rowley is an academic researcher from Hackensack University Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 23, co-authored 85 publications receiving 2117 citations. Previous affiliations of Scott D. Rowley include MedStar Georgetown University Hospital & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen,Catherine M. Bollard,Adam Mendizabal,Elizabeth J. Shpall,Paul Szabolcs,Joseph H. Antin,Neena Kapoor,Sung-Yun Pai,Sung-Yun Pai,Scott D. Rowley,Partow Kebriaei,Bimalangshu R. Dey,Bambi Grilley,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop +18 more
TL;DR: The use of banked third-party VSTs is a feasible and safe approach to rapidly treat severe or intractable viral infections after stem cell transplantation.
Journal ArticleDOI
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan,Marcelo C. Pasquini,Brent R. Logan,Edward A. Stadtmauer,David H. Vesole,Edwin P. Alyea,Joseph H. Antin,Raymond L. Comenzo,Stacey Goodman,Parameswaran Hari,Ginna G. Laport,Muzaffar H. Qazilbash,Scott D. Rowley,Firoozeh Sahebi,George Somlo,Dan T. Vogl,Daniel J. Weisdorf,Marian Ewell,Juan Wu,Nancy L. Geller,Mary M. Horowitz,Sergio Giralt,David G. Maloney +22 more
TL;DR: Non-myeloablative allogeneic HSCT after autologous HSCT is not more effective than tandem autologously HSCT for patients with standard-risk multiple myeloma and further enhancement of the graft versus myelomas effect and reduction in transplant-related mortality are needed.
Journal ArticleDOI
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Charles A. Schiffer,Kari Bohlke,Meghan Delaney,Heather Hume,Anthony J. Magdalinski,Jeffrey McCullough,James L. Omel,John M. Rainey,Paolo Rebulla,Scott D. Rowley,Michael B. Troner,Kenneth C. Anderson +11 more
TL;DR: This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in 2001 and is based on a systematic review of the medical literature published from September 1, 2014, through October 26, 2016.
Journal ArticleDOI
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
Mary Eapen,Brent R. Logan,Dennis L. Confer,Michael Haagenson,John E. Wagner,Daniel J. Weisdorf,John R. Wingard,Scott D. Rowley,David F. Stroncek,Adrian P. Gee,Mary M. Horowitz,Claudio Anasetti +11 more
TL;DR: The higher rate of cGVHD after PBSC transplants and, consequently, more frequent late adverse events warrant extended follow up of PBSC recipients, and a survival advantage with PBSC grafts in patients receiving unrelated donor transplants for advanced leukemia is identified.
Journal ArticleDOI
Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.
TL;DR: No deleterious effects from the use of red cell-incompatible hematopoietic grafts on transplant outcomes, such as granulocyte and platelet engraftments, the incidences of acute or chronic GvHD, relapse risk or OS have been consistently demonstrated.